Previous 10 | Next 10 |
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 26, 2021 (GLOBE NEWSWIRE) -- Merus N.V . (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), today announced that Bill Lundberg...
Yesterday, after the close, Merus (MRUS) updated interim data for its bispecific antibody zenocutuzumab (Zeno) in a phase 1/2 eNRGY trial targeting patients with NRG1+ cancers.The data was included in an abstract related to a presentation at the upcoming American Society of Clinical...
Gainers: Big Rock Partners Acquisition (BRPA) +86%.Euro Tech Holdings (CLWT) +32%.Urban One (UONE) +28%.Sensei Biotherapeutics (SNSE) +28%.BBQ Holdings (BBQ) +22%.PDS Biotechnology (PDSB) +20%.Advanced Emissions Solutions (ADES) +19%.Progenity (PROG) +18%.Moxian (MOXC) +16%.Precipio (PRP...
Merus N.V. (MRUS) highlighted the benefit of Zenocutuzumab in pancreatic cancer with the announcement of an abstract regarding the experimental cancer therapy which is part of a presentation at the American Society of Clinical Oncology ((ASCO)) 2021 Annual Meeting.The interim data a...
- 51 patients with NRG1+ cancer have been treated, including 33 patients evaluable for response, as of the January 12, 2021, data cutoff date - Encouraging early clinical activity observed, with confirmed partial responses in 4 of 10 patients with pancreatic cancer...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), today announced new collaborat...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 11, 2021 (GLOBE NEWSWIRE) -- Merus N.V . (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., Chi...
Merus (MRUS): Q1 GAAP EPS of -$0.28 misses by $0.10.Revenue of $8.35M (+32.5% Y/Y) misses by $9.7M.Press Release For further details see: Merus EPS misses by $0.10, misses on revenue
Merus N.V. (MRUS) announces that the first patient has been treated in its phase 1/2 dose escalation and expansion trial evaluating MCLA-129 for the treatment of patients with advanced non-small cell lung cancer ((NSCLC)) and other solid tumors.The phase 1/2, open-label clinical trial of...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 03, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific ...
News, Short Squeeze, Breakout and More Instantly...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 24, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), tod...
2024-07-13 04:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), tod...